Universität zu Köln

Al-Sawaf, Othman, Eichhorst, Barbara and Hallek, Michael (2020). Chronic lymphocytic leukemia. Internist, 61 (3). S. 277 - 288. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Full text not available from this repository.

Abstract

Chronic lymphocytic leukemia (CLL) is one of the most common hematological neoplasms and is the most common leukemia in western industrial nations. According to the World Health Organization classification, CLL is an indolent B-cell non-Hodgkin's lymphoma (NHL). Diagnosis requires an increase of B-lymphocytes to more than 5.0 & x202f;G/l as well as detection of CD5- and CD19-positive B-lymphocytes. Symptoms can be B symptoms, fatigue or frequent infections. Therapy is only required if there are pronounced symptoms or changes in the blood count, such as a relevant drop in hemoglobin and/or platelets. The prognosis strongly depends on the individual molecular and cytogenetic risk factors. For a long time, the first-line treatment was characterized by chemotherapy in combination with CD20 antibodies. In recent years, the approval of new targeted drugs has changed the treatment landscape significantly and has led to a shift towards chemotherapy-free regimens.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Al-Sawaf, Othman UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-344996
DOI:	10.1007/s00108-019-00733-8
Journal or Publication Title:	Internist
Volume:	61
Number:	3
Page Range:	S. 277 - 288
Date:	2020
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-1289
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OPEN-LABEL; RITUXIMAB; CLL; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL; OBINUTUZUMAB; VENETOCLAX; IBRUTINIB Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/34499